In a clinical trial, the company's weight loss pill resulted in a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medication. On average, participants lost 7.8% to ...

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

A series of lawsuits have been filed in Marion County court alleging that drug manufacturer Eli Lilly downplayed the side effects of its obesity and diabetes drugs.

The S&P 500 slid 0.1% on Thursday, Aug. 7, 2025, as new tariffs took effect, raising import duties on goods from numerous U.S. trading partners.

Eli Lilly’s obesity pill, orforglipron, has shown promising results in a late-stage trial, with patients losing almost 12% of ...

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

Lilly’s stock tumbled as disappointing trial data for an oral weight-loss pill offset an upbeat earnings report and outlook.

GLP-1's, which are traditionally diabetes medications, have exploded in popularity since they were approved for weight-loss.

Eli Lilly stock crashes as late-stage data for weight-loss pill falls short of expectations. Analyst explains why data wasn't ...

ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the ...